$CDNA

Hanna John Walter JR sold $4.5M of CDNA

Hanna John Walter JR (President and CEO) sold 118,000 shares of CareDx, Inc. (CDNA) at an average of $37.79 ($36.11–$39.01, $4.46M total) across 2 trades on 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Hanna John Walter JR
Published Jul 17, 2026, 8:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 17, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CDNA
Neutral
medium confidence
Mentioned
$CDNA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDNANeutralLow
01

Why it matters

The newest fact is the disclosed sale size, price range, and that it was executed under a pre-arranged 10b5-1 plan, which generally lowers the informational content versus discretionary selling.

02

Market read

This is a primary-source insider sale disclosure; it may slightly influence sentiment but is unlikely to change valuation absent additional fundamental news.

03

What to watch

The filing does not disclose new company fundamentals; traders should avoid extrapolating the sale into guidance or business deterioration without corroborating news.

Relevance 5/10Novelty 4/10Timing: after-hours, following the Form 4 filing on 2026-07-17

Background

The article is an SEC Form 4 insider transaction disclosure for CareDx, Inc. (CDNA) by its CEO/President.

Company-level read

Ticker impact

$CDNANeutralMedium confidence
Context

CareDx CEO and President Hanna John Walter Jr sold 118,000 shares in open-market transactions totaling about $4.46M, per Form 4 filed today.

Expected impact

Likely limited immediate price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a primary-source insider transaction disclosure, but it explicitly states a pre-arranged 10b5-1 plan, which reduces interpretive weight versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider activity without operational or financial disclosures.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • CareDx, Inc.

    Company whose insider transaction is disclosed on Form 4 (CDNA).

  • Hanna John Walter Jr

    President and CEO who sold 118,000 shares in open-market transactions.

  • 10b5-1 plan

    Pre-arranged plan cited as Yes, indicating the trades were scheduled in advance.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CDNAMed

CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?

CareDx (CDNA) shares rose 13% to $61.37 on high volume, following a price target increase to $74 by BTIG. Q2 2026 revenue grew 52% YoY, with testing services up 61%. Q3 earnings are expected at $0.24 per share, down 14.3% YoY, and revenue at $122.35M, up 22.3% YoY. The stock has a Zacks Rank of #2 (Buy). Charles River Laboratories (CRL), another medical services company, closed up 6.2% at $294.44, with a Zacks Rank of #2 (Buy).